Mainz Biomed B.V. (MYNZ)

NASDAQ: MYNZ · IEX Real-Time Price · USD
1.030
+0.010 (0.98%)
At close: Mar 28, 2024, 3:58 PM
1.020
-0.010 (-0.97%)
After-hours: Mar 28, 2024, 5:02 PM EDT
0.98%
Market Cap 20.56M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 16.75M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,707
Open 1.030
Previous Close 1.020
Day's Range 1.007 - 1.030
52-Week Range 0.850 - 6.600
Beta 0.17
Analysts Buy
Price Target 3.00 (+191.26%)
Earnings Date May 14, 2024

About MYNZ

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany. [Read more]

Sector Healthcare
IPO Date Nov 5, 2021
Employees 58
Stock Exchange NASDAQ
Ticker Symbol MYNZ
Full Company Profile

Financial Performance

In 2022, MYNZ's revenue was $529,877, a decrease of -8.22% compared to the previous year's $577,348. Losses were -$26.39 million, 125.7% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for MYNZ stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 191.26% from the latest price.

Price Target
$3.0
(191.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

10 days ago - GlobeNewsWire

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

11 days ago - GlobeNewsWire

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

17 days ago - GlobeNewsWire

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration Mainz Biomed's Pivotal FDA PMA clinical ...

23 days ago - GlobeNewsWire

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

BERKELEY, Calif. and MAINZ, Germany, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

4 weeks ago - GlobeNewsWire

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

BERKELEY, Calif. and MAINZ, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

5 weeks ago - GlobeNewsWire

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

5 weeks ago - GlobeNewsWire

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

BERKELEY, Calif. and MAINZ, Germany, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

7 weeks ago - GlobeNewsWire

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

2 months ago - GlobeNewsWire

Mainz Biomed Provides Year-End Corporate Review 2023

European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced Adenoma exceeding competition ReconAAsense designed to eva...

2 months ago - GlobeNewsWire

Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study

Mainz Biomed N.V. MYNZ recently released the results of its ColoFuture study in the American healthcare market.

3 months ago - Benzinga

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

3 months ago - GlobeNewsWire

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

3 months ago - GlobeNewsWire

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Groundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82% Results Exceed those from the Company's European ColoFuture ...

4 months ago - GlobeNewsWire

Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

4 months ago - GlobeNewsWire

Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference

BERKELEY, Calif. and MAINZ, Germany, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

4 months ago - GlobeNewsWire

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023 ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% wi...

4 months ago - GlobeNewsWire

Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering

BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

4 months ago - GlobeNewsWire

Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering

BERKELEY, Calif. and MAINZ, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

4 months ago - GlobeNewsWire

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

5 months ago - GlobeNewsWire

Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA

BERKELEY, Calif. and MAINZ, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

5 months ago - GlobeNewsWire

Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper

BERKELEY, Calif. and MAINZ, Germany, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl...

5 months ago - GlobeNewsWire

Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

Former Natera Manager will oversee all aspects of sales and support in EMEA, ensuring the continued commercialization of ColoAlert ® across the region BERKELEY, Calif. and MAINZ, Germany, Oct. 26, 202...

5 months ago - GlobeNewsWire

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study

Results indicate a substantial and meaningful enhancement in the effectiveness of non-invasive colorectal cancer (CRC) screening, particularly for the detection of advanced adenomas, a precursor to CR...

5 months ago - GlobeNewsWire

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

BERKELEY, Calif. and MAINZ, Germany, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early...

6 months ago - GlobeNewsWire